Company & Sponsor Intelligence
Merck Sharp & Dohme LLC
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials9
Recruiting3
Completed6
Countries2
Therapeutic footprint
parkinsonsunclassified
Indexed studies
NCT00505843A Study of MK0657 in Parkinson's Disease Patients (0657-006)
parkinsons · PHASE1
parkinsons · PHASE1
NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
parkinsons · United StatesPHASE3
parkinsons · United StatesPHASE3
NCT00777608A Study to Test the Performance of the CogState Computerized Neuropsychological Battery in Patients With Alzheimer's Disease (0000-086)(COMPLETED)
alzheimers · PHASE1
alzheimers · PHASE1
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
parkinsons · United StatesPHASE3
parkinsons · United StatesPHASE3
NCT06036836Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
NCT01294800A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)
parkinsons · PHASE2
parkinsons · PHASE2
NCT04305054Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
parkinsons · United StatesPHASE1,PHASE2
parkinsons · United StatesPHASE1,PHASE2
NCT07252739KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
unclassified · United StatesPHASE3
unclassified · United StatesPHASE3
NCT05064059A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
unclassified · United StatesPHASE3
unclassified · United StatesPHASE3
NCT04317066A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)
unclassified · JapanPHASE1
unclassified · JapanPHASE1
NCT03631407Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
unclassified · United StatesPHASE2
unclassified · United StatesPHASE2
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →